deltatrials
Terminated OBSERVATIONAL NCT00273858

Study Evaluating the Safety of Etanercept in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis

Open Label Study To Evaluate The Safety Profile And The Quality Of Life In Patients Receiving Etanercept For The Treatment Of Rheumatoid Arthritis, Ankylosing Spondylitis And Psoriatic Arthritis

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Conditions Ankylosing Spondylitis Arthritis, Psoriatic Arthritis, Rheumatoid Spondylitis, Ankylosing
Interventions There is no Intervention. The study is observational.
Updated 10 times since 2017 Last updated: Sep 8, 2011 Started: Mar 31, 2006 Primary completion: Jul 31, 2010 Completion: Jul 31, 2010
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study was terminated because at least one year follow-up was achieved for each patient and the achievement of 965 exposure years to the drug.

Other terminated trials from Wyeth is now a wholly owned subsidiary of Pfizer

See all terminations from Wyeth is now a wholly owned subsidiary of Pfizer

Other Ankylosing Spondylitis trials with similar outcome

Browse all Ankylosing Spondylitis trials

This observational or N/A phase trial investigates Ankylosing Spondylitis and Arthritis, Psoriatic and is currently terminated or withdrawn. Wyeth is now a wholly owned subsidiary of Pfizer leads this study, which shows 10 recorded versions since 2006 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Aug 2017 · 7 months · monthly snapshotTerminated~Aug 2017 – ~Apr 2018 · 8 months · monthly snapshotTerminated~Apr 2018 – ~May 2018 · 30 days · monthly snapshotTerminated~May 2018 – ~Jun 2018 · 31 days · monthly snapshotTerminated~Jun 2018 – ~Nov 2020 · 29 months · monthly snapshotTerminated~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshotTerminated~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotTerminated~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 24 months · monthly snapshotTerminated

Change History

10 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated

  3. Dec 2021 — Jul 2024 [monthly]

    Terminated

  4. Jan 2021 — Dec 2021 [monthly]

    Terminated

  5. Nov 2020 — Jan 2021 [monthly]

    Terminated

▶ Show 5 earlier versions

  1. Jun 2018 — Nov 2020 [monthly]

    Terminated

  2. May 2018 — Jun 2018 [monthly]

    Terminated

  3. Apr 2018 — May 2018 [monthly]

    Terminated

    Phase: NA → None

  4. Aug 2017 — Apr 2018 [monthly]

    Terminated NA

  5. Jan 2017 — Aug 2017 [monthly]

    Terminated NA

    First recorded

Mar 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Wyeth is now a wholly owned subsidiary of Pfizer
Data source: Wyeth is now a wholly owned subsidiary of Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations